Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

Medicine and Dentistry

• Heart Left Ventricle Ejection Fraction 100%
• Obstruction 100%
• Hypertrophic Obstructive Cardiomyopathy 100%
• Adverse Event 40%
• Ventricular Outflow Tract 40%
• Implantable Automatic Defibrillator 20%
• Atrial Fibrillation 20%
• Cardiovascular Disease 20%
• Pharmacokinetics 20%
• Pharmacodynamics 20%
• Drug Dose Reduction 20%
• Congestive Heart Failure 20%
• Titrimetry 20%
• Treatment Interruption 20%
• New-Onset Atrial Fibrillation 20%
• Cardiac Myosin 20%
• Major Adverse Cardiac Event 20%
• Placebo 20%
• Treatment Group 20%

Keyphrases

• Safety Efficacy 100%
• Safety Profile 100%
• Hypertrophic Obstructive Cardiomyopathy 100%
• Aficamten 100%
• Left Ventricular Ejection Fraction 38%
• Treatment-related Adverse Events 15%
• Left Ventricular Outflow Tract Gradient 15%
• Heart Failure 7%
• Placebo 7%
• Major Adverse Cardiovascular Events 7%
• Atrial Fibrillation 7%
• Site-based 7%
• Dosing Algorithm 7%
• Treatment Group 7%
• Baseline Characteristics 7%
• Pharmacokinetics-pharmacodynamics (PK-PD) 7%
• Unique Identifier 7%
• Treatment Duration 7%
• Dose Reduction 7%
• Adverse Cardiac Events 7%
• Implantable Defibrillator 7%
• Titration 7%
• Lowest Effective Dose 7%
• Treatment Interruption 7%
• Hypercontractivity 7%
• Per-protocol 7%
• New-onset Atrial Fibrillation 7%
• Valsalva 7%
• Cardiac Myosin Activator 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Obstruction 100%
• Hypertrophic Obstructive Cardiomyopathy 100%
• Adverse Event 66%
• Pharmacodynamics 33%
• Placebo 33%
• Congestive Heart Failure 33%
• New-Onset Atrial Fibrillation 33%
• Major Adverse Cardiac Event 33%
• Cardiac Myosin 33%
• Atrial Fibrillation 33%
• Cardiovascular Disease 33%
• Pharmacokinetics 33%
• Treatment Group 33%